The Benefit of Hemodialysis Plus Hemoperfusion on Mortality

Launched by XINHUA HOSPITAL, SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE · Jul 20, 2017

Keywords

ClinConnect Summary

In this HD/HPvsHD trial, we plan to enroll 1364 maintenance hemodialysis patients. Eleven medical centers in Shanghai Metropolitan area have explicitly expressed interest to participate. Participants will be randomized to receive hemodialysis plus hemoperfusion or hemodialysis alone at a 1:1 ratio after 1-month run-in period. In both arms, patients will receive lBlood purification (including low-flux hemodialysis, high-flux hemodialysis, or hemodiafiltration) treatment at least 10 hours per week. In the experiment group, in addition to the treatments in the control arm, hemoperfusion will b...

Gender

ALL

Eligibility criteria

• Patients must meet all of the following criteria are eligible:
• • 1. Age ≥ 18 years old
• • 2. Regular blood purification treatment at least 3 months before enrolled in this study
• • 3) Standard Kt/V ≥ 1.2
• Subjects with one of more of the following conditions will be excluded:
• • 1. White blood cell count \< 4×10\^9/L and / or platelet count \< 100×10\^9/L
• • 2. Cerebral hemorrhage in the past 12 weeks
• • 3. MACEs in the past 8 weeks
• • 4. Severe heart failure (New York Heart Association \[NYHA\] class IV)
• • 5. Active gastrointestinal bleeding, or coagulation dysfunction
• • 6. Malignant tumor
• • 7. Active infection
• • 8. Pregnancy or lactation 9) Mental disabilities